Search

Your search keyword '"Uncos, Alejandro"' showing total 8 results
Start Over Author "Uncos, Alejandro"
8 results on '"Uncos, Alejandro"'

1. Parasitological and molecular search for Leishmania natural infection in phlebotomine sand flies in peri-urban and rural sites of an Argentinean area endemic for tegumentary leishmaniasis

Author

Almazán, María Cristina, primary, Copa, Griselda Noemí, additional, Gil, José Fernando, additional, López Quiroga, Inés, additional, Díaz Fernández, Melisa Evangelina, additional, Uncos, Alejandro, additional, Hoyos, Carlos Lorenzo, additional, Nasser, Julio Rubén, additional, Barroso, Paola Andrea, additional, and Marco, Jorge Diego, additional

Published
2021
Full Text
View/download PDF

2. Simultaneous occurrence of cutaneous and mucocutaneous leishmaniasis caused by different genotypes of Leishmania (Viannia) braziliensis

Author

Hoyos, Carlos L., primary, Quipildor, Marcelo, additional, Bracamonte, Estefanía, additional, Lauthier, Juan J., additional, Cajal, Pamela, additional, Uncos, Alejandro, additional, Korenaga, Masataka, additional, Hashiguchi, Yoshihisa, additional, Barroso, Paola A., additional, and Marco, Jorge D., additional

Published
2019
Full Text
View/download PDF

3. Experimental Evidence of Biological Interactions among Different Isolates of Trypanosoma cruzi from the Chaco Region

Author

Ragone, Paula G., primary, Pérez Brandán, Cecilia, additional, Monje Rumi, Mercedes, additional, Tomasini, Nicolás, additional, Lauthier, Juan J., additional, Cimino, Rubén O., additional, Uncos, Alejandro, additional, Ramos, Federico, additional, Alberti D´Amato, Anahí M., additional, Basombrío, Miguel A., additional, and Diosque, Patricio, additional

Published
2015
Full Text
View/download PDF

4. A Monoallelic Deletion of the TcCRT Gene Increases the Attenuation of a Cultured Trypanosoma cruzi Strain, Protecting against an In Vivo Virulent Challenge

Author

Sánchez-Valdéz, Fernando J., primary, Pérez Brandán, Cecilia, additional, Ramírez, Galia, additional, Uncos, Alejandro D., additional, Zago, M. Paola, additional, Cimino, Rubén O., additional, Cardozo, Rubén M., additional, Marco, Jorge D., additional, Ferreira, Arturo, additional, and Basombrío, Miguel Ángel, additional

Published
2014
Full Text
View/download PDF

6. USE OF THE POLYMERASE CHAIN REACTION (PCR)FOR EARLY EVALUATION

Author

Lacunza, Carlos Diego, primary, Negrete, Olga Sánchez, additional, Mora, María Celia, additional, Uncos, Alejandro, additional, Segura, María Asunción, additional, Del Castillo, Néstor, additional, Garayzabal, María Isabel, additional, and Basombrío, Miguel Ángel, additional

Published
2007
Full Text
View/download PDF

7. A Monoallelic Deletion of the TcCRT Gene Increases the Attenuation of a Cultured Trypanosoma cruzi Strain, Protecting against an In Vivo Virulent Challenge.

Author

Sánchez-Valdéz, Fernando J., Pérez Brandán, Cecilia, Ramírez, Galia, Uncos, Alejandro D., Zago, M. Paola, Cimino, Rubén O., Cardozo, Rubén M., Marco, Jorge D., Ferreira, Arturo, and Basombrío, Miguel Ángel

Subjects
TRYPANOSOMA cruzi, MICE, VACCINATION, DEATH (Biology), IMMUNE response
Abstract

Trypanosoma cruzi calreticulin (TcCRT) is a virulence factor that binds complement C1, thus inhibiting the activation of the classical complement pathway and generating pro-phagocytic signals that increase parasite infectivity. In a previous work, we characterized a clonal cell line lacking one TcCRT allele (TcCRT+/−) and another overexpressing it (TcCRT+), both derived from the attenuated TCC T. cruzi strain. The TcCRT+/− mutant was highly susceptible to killing by the complement machinery and presented a remarkable reduced propagation and differentiation rate both in vitro and in vivo. In this report, we have extended these studies to assess, in a mouse model of disease, the virulence, immunogenicity and safety of the mutant as an experimental vaccine. Balb/c mice were inoculated with TcCRT+/− parasites and followed-up during a 6-month period. Mutant parasites were not detected by sensitive techniques, even after mice immune suppression. Total anti-T. cruzi IgG levels were undetectable in TcCRT+/− inoculated mice and the genetic alteration was stable after long-term infection and it did not revert back to wild type form. Most importantly, immunization with TcCRT+/− parasites induces a highly protective response after challenge with a virulent T. cruzi strain, as evidenced by lower parasite density, mortality, spleen index and tissue inflammatory response. TcCRT+/− clones are restricted in two important properties conferred by TcCRT and indirectly by C1q: their ability to evade the host immune response and their virulence. Therefore, deletion of one copy of the TcCRT gene in the attenuated TCC strain generated a safe and irreversibly gene-deleted live attenuated parasite with high immunoprotective properties. Our results also contribute to endorse the important role of TcCRT as a T. cruzi virulence factor. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

8. Serological Evaluation of Specific-Antibody Levels in Patients Treated for Chronic Chagas' Disease

Author

Sa´nchez Negrette, Olga, Sa´nchez Valde´z, Fernando J., Lacunza, Carlos D., Garci´a Bustos, Mari´a Fernanda, Mora, Mari´a Celia, Uncos, Alejandro D., and Basombri´o, Miguel A´ngel

Abstract

ABSTRACTSerological tests are the main laboratory procedures used for diagnosis during the indeterminate and chronic stages of Chagas' disease. A serological regression to negativity is the main criterion used to define parasitological cure in treated patients. The aim of this work was to monitor the individual specificities of antibody levels for 3 years posttreatment in 18 adult patients. Conventional serological techniques (hemagglutination assays and enzyme-linked immunosorbent assay [ELISA]) were modified by using recombinant antigens to detect early markers of treatment effectiveness. For this purpose, serum samples were taken before and during treatment and every 6 months after treatment for at least 3 years. When hemagglutination assays were used, a decrease in antibody levels was observed in only one patient. When ELISA with serum dilutions was used, antibody clearance became much more apparent: in 77.7% (14/18) of the patients, antibody titers became negative with time. This was observed at serum dilutions of 1/320 and occurred between the 6th and the 30th months posttreatment. The immune response and the interval for a serological regression to negativity were different for each patient. For some of the recombinant antigens, only 50% (9/18) of the patients reached the serological regression to negativity. Recombinant antigen 13 might be a good marker of treatment effectiveness, since 66.6% (six of nine) of the patients presented with an early regression to negativity for specific antibodies to this antigen (P= 0.002).

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results